Lymphocyte activation gene 3 (LAG-3) is a cell surface inhibitory receptor with multiple
biological activities over T cell activation and effector functions. LAG-3 plays a regulatory role in …

Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since
the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (…

Highlights • LAG-3 is a highly important next-generation immune checkpoint molecule. •
Ninety-seven clinical trials are evaluating at least 16 LAG-3-targeting molecules. • Here we …

PD-L1/PD-1 blockade immunotherapy has significantly improved treatment outcome for
several cancer types compared to conventional cytotoxic therapies. However, the specific …

Hyperprogressive disease (HPD) is an adverse outcome of immunotherapy consisting of an
acceleration of tumor growth associated with prompt clinical deterioration. The definitions …

Resistance of melanoma to targeted therapy and immunotherapy is linked to metabolic
rewiring. Here, we show that increased fatty acid oxidation (FAO) during prolonged BRAF …

Simple Summary Immunotherapy has been positioned as frontline therapy for advanced non-small
cell lung cancer (NSCLC), alone when PD-L1 tumor expression is high, or combined …

Recent studies highlight the importance of baseline functional immunity for immune
checkpoint blockade therapies. High‐dimensional systemic immune profiling is performed in a …

Along with the positioning of immunotherapy as a preferential treatment for a wide variety of
neoplasms, a new pattern of response consisting in a sudden acceleration of tumor growth …

The development of cancer immunotherapy in the last decade has followed a vertiginous
rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 …